DelistingOct 30, 2026, 04:07 PM
Actuate Therapeutics Faces Nasdaq Delisting Warning for Low Stock Price
AI Summary
Actuate Therapeutics, Inc. received a notice from Nasdaq indicating its common stock has closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has an initial 180-day period, until April 26, 2027, to regain compliance. Failure to do so could lead to a second compliance period if it seeks to transfer to the Nasdaq Capital Market. This notice is separate from a prior notification regarding the minimum market value of listed securities, which has a compliance deadline of January 11, 2027.
Key Highlights
- Actuate Therapeutics received notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00.
- The company has 180 days, until April 26, 2027, to regain compliance by having its stock close at $1.00 for 10 consecutive business days.
- Failure to comply may result in a second 180-day period if the company applies to transfer to the Nasdaq Capital Market.
- The company is also addressing a separate notice from Nasdaq regarding minimum market value of listed securities (MVLS) with a compliance deadline of January 11, 2027.
Price Impact
More from ACTU